Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications

Circulation

Volumn 113, Issue 10, 2006, Pages 1353-1360

  Koka, Vijay ^a   Wang, Wansheng ^a   Xiao, Ru Huang ^a   Shokei, Kim Mitsuyama ^b   Truong, Luan D ^c   Lan, Hui Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Angiotensin; Arteriosclerosis; Coronary disease; Diabetes mellitus; Kidney

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CAPTOPRIL; CHYMASE; CHYMOSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TESTOLACTONE; VALSARTAN; RAGE PROTEIN, HUMAN; SERINE PROTEINASE; TUMOR ANTIGEN;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL ARTERY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; ADULT; AGED; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; UPREGULATION;

ADULT; AGED; ANGIOTENSIN II; ANTIGENS, NEOPLASM; CHYMASES; DIABETIC ANGIOPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; SERINE ENDOPEPTIDASES; UP-REGULATION;

EID: 33645746010     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.575589     Document Type: Article

References (34)

1. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27:S68-S71.
2. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am j Cardiol. 1993;72:H14-H21.
3. Cooper ME The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2001;17:16S-20S
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713-718.
5. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A.
6. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin ii formation in human vascular tissue. Circulation. 1999;100:654-658.
7. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Jemtel TL. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844-846.
8. Wei CC, Tian B, Perry G, Meng QC, Chen YF, Oparil S, Dell'Italia LJ. Differential Ang II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am J Physiol Heart Circ Physiol. 2002;282:H2254-H2258.
9. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
10. MaassenVanDenBrink A, de Vries R, Saxena PR, Schalekamp MA, Danser AH. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res. 1999;44:407-415.
11. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738-1747.
12. Miyake-Ogawa C, Miyazaki M, Abe K, Harada T, Ozono Y, Sakai H, Koji T, Kohno S. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol. 2003;25:1-12.
13. Takai S, Jin D, Muramatsu M, Miyazaki M. Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci. 2004;25:518-522.
14. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci U S A. 2001;98:7469-7474.
15. Takai S, Jin D, Muramatsu M, Okamoto Y, Miyazaki M Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur J Pharmacol. 2004;6:501:1-8.
16. Peters S, Trummel M, Meyners W, Koehler B, Westermann K. Valsartan versus ACE inhibition after bare metal stent implantation: results of the VALVACE trial. Int J Cardiol. 2005;98:331-335.
17. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
18. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63:1874-1880.
19. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation end-products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447-456.
20. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53:1813-1823.
21. Ritz E. Chymase: a potential culprit in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1952-1954.
22. Lan HY, Mu W, Nickolic-Paterson DJ, Atkins RC. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem. 1995;43:97-102.
23. Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, Lan HY. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol. 2004;164:1389-1397.
24. Kawano H, Kim S, Ohta K, Nakao T, Miyazaki H, Nakatani T, Iwao H. Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced mesangial cell proliferation and gene expression. J Am Soc Nephrol. 2003;14:584-592.
25. Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, Hoshiga M, Kaneda Y, Morishita R, Zhan Y, Iwao H. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res. 2001;88:1120-1111.
26. Lundequist A, Tchougounova E, Abrink M, Pejler G. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J Biol Chem. 2004;279:32339-32344.
27. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14:475-486.
28. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet. 2000;350(suppl):S19-S113.
29. Cooper ME. Interaction of metabolic and hemodynamic factors in mediating experimental diabetic nephropathy. Diabetes. 2001;14:475-486.
30. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
31. Ahmed N. Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67:3-21.
32. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res. 2003;23:129-134.
33. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003;93:1159-1169.
34. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2004;18:176-178.